451 related articles for article (PubMed ID: 10389911)
1. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
2. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
3. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
Disis ML; Schiffman K; Guthrie K; Salazar LG; Knutson KL; Goodell V; dela Rosa C; Cheever MA
J Clin Oncol; 2004 May; 22(10):1916-25. PubMed ID: 15143085
[TBL] [Abstract][Full Text] [Related]
4. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.
Disis ML; Gralow JR; Bernhard H; Hand SL; Rubin WD; Cheever MA
J Immunol; 1996 May; 156(9):3151-8. PubMed ID: 8617935
[TBL] [Abstract][Full Text] [Related]
5. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
6. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
[TBL] [Abstract][Full Text] [Related]
7. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.
Salazar LG; Fikes J; Southwood S; Ishioka G; Knutson KL; Gooley TA; Schiffman K; Disis ML
Clin Cancer Res; 2003 Nov; 9(15):5559-65. PubMed ID: 14654536
[TBL] [Abstract][Full Text] [Related]
8. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
9. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
Disis ML; Gooley TA; Rinn K; Davis D; Piepkorn M; Cheever MA; Knutson KL; Schiffman K
J Clin Oncol; 2002 Jun; 20(11):2624-32. PubMed ID: 12039923
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
11. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
[TBL] [Abstract][Full Text] [Related]
13. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
Zaks TZ; Rosenberg SA
Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
[TBL] [Abstract][Full Text] [Related]
14. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of HER-2/neu-specific vaccines.
Murray JL; Przepiorka D; Ioannides CG
Semin Oncol; 2000 Dec; 27(6 Suppl 11):71-5; discussion 92-100. PubMed ID: 11236031
[TBL] [Abstract][Full Text] [Related]
16. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.
Salazar LG; Coveler AL; Swensen RE; Gooley TA; Goodell V; Schiffman K; Disis ML
Clin Immunol; 2007 Dec; 125(3):275-80. PubMed ID: 17913588
[TBL] [Abstract][Full Text] [Related]
19. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Kao TC; Shriver CD; Ponniah S; Peoples GE
Clin Cancer Res; 2006 Jan; 12(2):478-86. PubMed ID: 16428490
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.
Kono K; Takahashi A; Sugai H; Fujii H; Choudhury AR; Kiessling R; Matsumoto Y
Clin Cancer Res; 2002 Nov; 8(11):3394-400. PubMed ID: 12429626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
